Results 1 to 10 of about 6,215 (156)

Elranatamab: A novel B-cell maturation T-cell engager [PDF]

Human Vaccines & Immunotherapeutics
B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies.
Shahrier Hossain, Giada Bianchi
doaj   +2 more sources

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

OncoImmunology, 2021
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse.
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angéla Virone-Oddos   +25 more
doaj   +2 more sources

Integrating T cell signaling and metabolism to enhance T cell engager responses in solid tumors [PDF]

Frontiers in Immunology
T cell engagers (TCEs) have delivered meaningful clinical benefit to patients, with eight molecules currently FDA-approved for hematologic malignancies and two approved for solid tumor indications.
Michael Scaglione, Minal Engavale, Matthew G Chun, Deepali V Sawant, Daniel R Lu, Edward LaGory   +5 more
doaj   +2 more sources

Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion [PDF]

mAbs
B cell maturation antigen (BCMA) is a validated target for plasma cell depletion; however, T cell–redirecting approaches must balance potent cytotoxicity with controlled T cell activation.
Jamie Thomas, Gang Xu, Hannah Lock, Qin Song, Yumei Yin, Wanying Luo, Kyu Hong, Liguang Lou, Changyu Wang, Leslie Chinn, Neelufar Mozaffarian, Jaideep Dudani, Paul Bessette, Charlie Zhou, Ruth Lan, Bo Chen, Nishant Mehta   +16 more
doaj   +2 more sources

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy [PDF]

Signal Transduction and Targeted Therapy
T cell engager (TCE) immunotherapies have revolutionized the landscape of cancer treatment; however, their efficacy remains limited by the inaccessibility of intracellular tumor antigens.
Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu   +7 more
doaj   +2 more sources

Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice [PDF]

Nature Communications
Tumor infiltrating T cells (TIL) are key players in the anti-tumor immune response. However, chronic exposure to tumor-derived antigens drives the differentiation into ‘exhausted’ TILs.
Xuhao Zhang, Yu Gao, Wenbo Hu, Yong Liang, Xiaozhe Yin, Xiangjun Shi, Hongjia Li, Huiping Liao, Jingya Guo, Xiaohong Yu, Mingzhao Zhu, Hua Peng, Wenyan Wang, Yang-Xin Fu   +13 more
doaj   +2 more sources

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Biomedicines, 2020
Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having substantial evidence of efficacy in patients with cancer. Bi- and tri-specific antibodies targeting tumor antigens and capable of activating T cell receptor signaling ...
Zong Sheng Guo, Michael T. Lotze, Zhi Zhu, Walter J. Storkus, Xiao-Tong Song   +4 more
doaj   +3 more sources

Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy [PDF]

Journal for ImmunoTherapy of Cancer
Background Bispecific T cell engagers have demonstrated promising clinical progress in both hematologic malignancies and solid tumors; however, their therapeutic efficacy is still limited by multiple challenges including T cell anergy resulting from ...
Qi Sun, Ying Wang, Qin Liu, Baorui Liu, Jie Shao, Fangcen Liu, Xiaotong Chen, Jingyi Guo, Mengzhu Li, Tianran Chen, Yuxiang Li, Jiayao Yan, Jiaqi Nie   +12 more
doaj   +2 more sources

Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy 
for SCLC [PDF]

Chinese Journal of Lung Cancer
Small cell lung cancer (SCLC), characterized by high aggressiveness, early metastasis, and poor prognosis, has long been a major challenge in lung cancer treatment.
Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology
doaj   +2 more sources

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Glioblastoma is the the most common primary brain tumor in adults. Onset of disease is followed by a uniformly lethal prognosis and dismal overall survival. While immunotherapies have revolutionized treatment in other difficult-to-treat cancers, these have failed to demonstrate significant clinical benefit in patients with glioblastoma.
Kirit Singh, Kelly M Hotchkiss, Aditya A Mohan, Jessica L Reedy, John H Sampson, Mustafa Khasraw   +5 more
openaire   +3 more sources